| scholarly article | Q13442814 |
| P2093 | author name string | Yue Yang | |
| Atul Deodhar | |||
| David H Collier | |||
| Bojena Bitman | |||
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
| Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment | Q34563216 | ||
| Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy | Q35177630 | ||
| Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study | Q35554431 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Integrated safety in tocilizumab clinical trials | Q35840716 | ||
| Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | Q35954510 | ||
| Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial | Q36640598 | ||
| Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 | ||
| Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment | Q37131883 | ||
| Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions | Q37415092 | ||
| High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis | Q37775403 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis | Q37977885 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores | Q47857433 | ||
| Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. | Q53725487 | ||
| Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects | Q73628316 | ||
| Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 | ||
| Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis | Q81922641 | ||
| Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis | Q85264043 | ||
| Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox | Q88035627 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 3045-3052 | |
| P577 | publication date | 2016-10-05 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis | |
| P478 | volume | 35 |
Search more.